PHAT Quote, Financials, Valuation and Earnings

Galectin Therapeutics has a net margin of -523.34% compared to Phathom Pharmaceuticals's net margin of --. Phathom Pharmaceuticals's return on equity of -- beat Galectin Therapeutics's return on equity of --.

Phathom Pharmaceuticals has a consensus price target of $22.00, signalling upside risk potential of 231.43%. On the other hand Galectin Therapeutics has an analysts' consensus of -- which suggests that it could grow by 1208.59%. Given that Galectin Therapeutics has higher upside potential than Phathom Pharmaceuticals, analysts believe Galectin Therapeutics is more attractive than Phathom Pharmaceuticals.

Phathom Pharmaceuticals has a beta of 0.562, which suggesting that the stock is 43.812% less volatile than S&P 500. In comparison Galectin Therapeutics has a beta of 0.689, suggesting its less volatile than the S&P 500 by 31.07%.

Phathom Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Galectin Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phathom Pharmaceuticals pays -- of its earnings as a dividend. Galectin Therapeutics pays out -- of its earnings as a dividend.

Phathom Pharmaceuticals quarterly revenues are $16.4M, which are larger than Galectin Therapeutics quarterly revenues of --. Phathom Pharmaceuticals's net income of -$85.6M is lower than Galectin Therapeutics's net income of -$11.2M. Notably, Phathom Pharmaceuticals's price-to-earnings ratio is -- while Galectin Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phathom Pharmaceuticals is 17.05x versus -- for Galectin Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Janux Therapeutics has a net margin of -523.34% compared to Phathom Pharmaceuticals's net margin of -6391.57%. Phathom Pharmaceuticals's return on equity of -- beat Janux Therapeutics's return on equity of -11.37%.

Phathom Pharmaceuticals has a consensus price target of $22.00, signalling upside risk potential of 231.43%. On the other hand Janux Therapeutics has an analysts' consensus of -- which suggests that it could grow by 63.23%. Given that Phathom Pharmaceuticals has higher upside potential than Janux Therapeutics, analysts believe Phathom Pharmaceuticals is more attractive than Janux Therapeutics.

Phathom Pharmaceuticals has a beta of 0.562, which suggesting that the stock is 43.812% less volatile than S&P 500. In comparison Janux Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Phathom Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Janux Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phathom Pharmaceuticals pays -- of its earnings as a dividend. Janux Therapeutics pays out -- of its earnings as a dividend.

Phathom Pharmaceuticals quarterly revenues are $16.4M, which are larger than Janux Therapeutics quarterly revenues of $439K. Phathom Pharmaceuticals's net income of -$85.6M is lower than Janux Therapeutics's net income of -$28.1M. Notably, Phathom Pharmaceuticals's price-to-earnings ratio is -- while Janux Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phathom Pharmaceuticals is 17.05x versus 220.32x for Janux Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of -523.34% compared to Phathom Pharmaceuticals's net margin of 18.95%. Phathom Pharmaceuticals's return on equity of -- beat Merck &'s return on equity of 29.26%.

Phathom Pharmaceuticals has a consensus price target of $22.00, signalling upside risk potential of 231.43%. On the other hand Merck & has an analysts' consensus of $128.73 which suggests that it could grow by 29.44%. Given that Phathom Pharmaceuticals has higher upside potential than Merck &, analysts believe Phathom Pharmaceuticals is more attractive than Merck &.

Phathom Pharmaceuticals has a beta of 0.562, which suggesting that the stock is 43.812% less volatile than S&P 500. In comparison Merck & has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.746%.

Phathom Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.14% to investors and pays a quarterly dividend of $0.81 per share. Phathom Pharmaceuticals pays -- of its earnings as a dividend. Merck & pays out 2039.73% of its earnings as a dividend.

Phathom Pharmaceuticals quarterly revenues are $16.4M, which are smaller than Merck & quarterly revenues of $16.7B. Phathom Pharmaceuticals's net income of -$85.6M is lower than Merck &'s net income of $3.2B. Notably, Phathom Pharmaceuticals's price-to-earnings ratio is -- while Merck &'s PE ratio is 20.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phathom Pharmaceuticals is 17.05x versus 4.00x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Poseida Therapeutics has a net margin of -523.34% compared to Phathom Pharmaceuticals's net margin of 28.2%. Phathom Pharmaceuticals's return on equity of -- beat Poseida Therapeutics's return on equity of -66.05%.

Phathom Pharmaceuticals has a consensus price target of $22.00, signalling upside risk potential of 231.43%. On the other hand Poseida Therapeutics has an analysts' consensus of $14.00 which suggests that it could grow by 0.11%. Given that Phathom Pharmaceuticals has higher upside potential than Poseida Therapeutics, analysts believe Phathom Pharmaceuticals is more attractive than Poseida Therapeutics.

Phathom Pharmaceuticals has a beta of 0.562, which suggesting that the stock is 43.812% less volatile than S&P 500. In comparison Poseida Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Phathom Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Poseida Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phathom Pharmaceuticals pays -- of its earnings as a dividend. Poseida Therapeutics pays out -- of its earnings as a dividend.

Phathom Pharmaceuticals quarterly revenues are $16.4M, which are smaller than Poseida Therapeutics quarterly revenues of $71.7M. Phathom Pharmaceuticals's net income of -$85.6M is lower than Poseida Therapeutics's net income of $20.2M. Notably, Phathom Pharmaceuticals's price-to-earnings ratio is -- while Poseida Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phathom Pharmaceuticals is 17.05x versus 6.09x for Poseida Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.